FAQ/Help |
Calendar |
Search |
Today's Posts |
|
10-30-2014, 11:03 AM | #1 | ||
|
|||
Member
|
Recruitment has begun at multiple sites across the US and around the world for the STEADY-PD Phase III trial to test the effectiveness of isradipine on slowing the progression of PD. Isradipine is a calcium channel blocker currently approved to treat hypertension. This is a very important study as there are very good pre-clinical studies to support the hypothesis of isradipine being neuroprotective; long-term epidemiology studies have shown a lower incidence of PD among people who take certain types of calcium channel blockers; the science behind the hypothesis makes a lot of biological and chemical sense; and the drug is already approved with a well known safety profile and minimal side effects.
The study is sponsored by The Parkinson Study Group (PSG) with support from the National Institute of Neurological Disorders and Stroke. MJFF helped fund the successful Phase II study. The link below provides more details and a list of site locations. The study is limited to early stage (less than 3 years) PWP. http://steadypd3.com/ |
||
Reply With Quote |
"Thanks for this!" says: | soccertese (10-31-2014) |
10-30-2014, 03:28 PM | #2 | ||
|
|||
Member
|
You must be drug free.
|
||
Reply With Quote |
10-30-2014, 08:52 PM | #3 | ||
|
|||
Senior Member
|
I believe this is a drug we tried off-label a few years ago: no effect. To be fair, perhaps you have to take it for a long time, and as BB99 noticed, you have to be drug free (meaning very early in the game) and I am pretty sure we were already taking sinemet when we tried it (with the approval/blessing of a very well known PD doc, I might add).
Hope it works for the newbies |
||
Reply With Quote |
10-30-2014, 10:09 PM | #4 | ||
|
|||
Member
|
Quote:
|
||
Reply With Quote |
"Thanks for this!" says: | Thelma (10-31-2014) |
10-31-2014, 12:00 AM | #5 | ||
|
|||
Member
|
Quote:
Regarding stem cell research, I too would like to see more of it, along with research in several other areas, like growth factors and vaccines to prevent protein misfolding. We all can have opinions, but no one knows in the end which will or won't work. |
||
Reply With Quote |
10-31-2014, 12:08 AM | #6 | ||
|
|||
Junior Member
|
Quote:
|
||
Reply With Quote |
"Thanks for this!" says: | Tupelo3 (10-31-2014) |
10-30-2014, 11:07 PM | #7 | ||
|
|||
Member
|
Quote:
The drug would not really be expected to have any symptomatic effect. It's use, according to the theory, would be to slow cell death and, hence, slow progression. So, yes, you would need to analyze the effects over years. The new study will be for three years. You don't have to be drug free to use isradipine. It has very little interaction with other drugs so take anything else you want. You have to be drug free for the trial only so the researchers can rule out their impact on any results. It's strictly due to study design. You don't need to be early stage to use the drug. Once again, this is strictly due to study design for two main reasons: first, as you said, it's easier to find people who aren't taking other drugs; and second, as with research on other potential neuroprotective interventions, you're more likely to find efficacy the earlier you begin treatment. There are more dopamine neurons left to save. I have researched this drug extensively over the past two years, including speaking with the lead investigators of this trial and biologists who specialize in basil ganglia health. I am also the PD advocate for this trial for the U of Penn and the Atlantic neurological Inst in NJ. I'm not going to give anyone any medical advice, but I would be more than happy to share what I learned with anyone interested. As someone who believes in using proper clinical trials to test hypotheses, I do hope this study gets the needed volunteers (336) so we can determine if the drugs really is neuroprtective. |
||
Reply With Quote |
"Thanks for this!" says: | soccertese (10-31-2014), Thelma (10-31-2014) |
10-31-2014, 08:28 PM | #8 | ||
|
|||
Member
|
Quote:
Thanks. |
||
Reply With Quote |
10-31-2014, 09:55 PM | #9 | ||
|
|||
Member
|
The trial is using a 10mg/day dose. 5mg twice a day. The lead investigators determined this to be optimal from the phase 2 trial. For hypertension, you can go up to 20mg. But, more side effects were observed at that dosage.
|
||
Reply With Quote |
"Thanks for this!" says: | aquario (11-02-2014) |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
Cogane phase II study recruitment is now complete | Parkinson's Disease | |||
Addex begins phase IIa trial of dipraglurant in Parkinson's disease levodopa-induced | Parkinson's Disease | |||
Encouraging Clinical trial recruitment | Parkinson's Disease | |||
Isradipine Clinical Trial - FYI | Parkinson's Disease | |||
Isradipine Clinical Trial | Parkinson's Disease |